• linkedin
  • Increase Font
  • Sharebar

    10 More Newly Approved Drugs

    The FDA is having a productive 2017.

     

    Ocrevus vial

    OCREVUS (ocrelizumab), Genentech

    Indications: A CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis.

    Dosage: Start dose is 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion and subsequent 600 mg intravenous infusion every 6 months.

    Contraindications: Active hepatitis B virus infection, history of life-threatening infusion reaction to OCREVUS.

    Read the prescribing information here

    Previous ButtonNext Button

     

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available
    Slideshows
    Small Doses: The Weekly News You Need to Know
    Small Doses: The Weekly News You ...

    Small doses is a weekly slideshow of the news you may have missed, made just for you and your busy lifestyle.

    25 Cities With The Lowest Pharmacist ...